

**IN THE CLAIMS:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A method of administering chemotherapy, comprising:  
administering a first agent that attenuates Topoisomerase I (Topo I) activity; and  
administering a second agent that inhibits Heat Shock Protein 90 (HSP90) activity,  
wherein the first agent and the second agent are administered either contemporaneously or sequentially.
2. (Previously presented) The method of claim 1 wherein the first agent is a compound selected from the group consisting of:
  - (i) compounds that bind to Topo I and inhibit its activity,
  - (ii) compounds which prevent the transcription, translation or expression of Topo I,
  - (iii) compounds which inhibit release of Topo I from intracellular stores, and
  - (iv) compounds which increase the rate of degradation of Topo I.
3. (Previously presented) The method of claim 1 wherein the first agent is a cleavable-complex inhibitor.
4. (Previously presented) The method of claim 1 wherein the first agent is Camptothecin.
5. (Previously presented) The method of claim 1 wherein the first agent is Topotecan.
6. (Previously presented) The method of claim 1 wherein the first agent is Irinotecan.

7. (Previously presented)The method of claim 1 wherein the first agent is Camptostar (CPT-11).
8. (Previously presented)The method of claim 1 wherein the first agent is Gemcitabine.
9. (Previously presented)The method of claim 1 wherein the second agent is a compound selected from the group consisting of:
  - (i) compounds that bind to HSP 90 and inhibit its activity,
  - (ii) compounds which prevent the transcription, translation or expression of HSP 90,
  - (iii) compounds which inhibit release of HSP 90 from intracellular stores, and
  - (iv) compounds which increase the rate of degradation of HSP 90.
10. (Previously presented)The method of claim 9 wherein the second agent is Geldanamycin.
11. (Previously presented)The method of claim 10 wherein the second agent is 17-Allylamino,17-demethoxygeldanamycin (17AAG) or CNF-101.
12. (Previously presented)The method of claim 9 wherein the second agent is Radicicol.
13. (Previously presented)The method of claim 1 wherein the chemotherapy is for cancer treatment.
14. (Previously presented)The method of claim 13 for the treatment of solid tumours.
15. (Previously presented)The method of claim 14 for the treatment of bowel cancer, small cell and non-small cell lung cancer, head and neck cancer, breast cancer, bladder cancer or malignant melanoma.

16. (Previously presented)The method of claim 15 for the treatment of paediatric tumours.
17. (Previously presented)The method of claim 13 ~~or 16~~ for the treatment of neuroblastoma, leukaemias and/or lymphomas.
18. (Previously presented)The method of claim 1 wherein the chemotherapy is for:
  - antibacterial treatments,
  - antifungal treatments,
  - antiparasitic treatments,
  - the treatment of AIDS/HIV,
  - the treatment of multiple sclerosis, or
  - the killing and inhibition of proliferation of any organism.
19. (Previously presented)The method of claim 1 wherein the chemotherapy is for prophylactic treatment.
- 20.-31. (Cancelled)